For instance, one effective approach could involve combining a mAb that amplifies the activity of preexisting tumor-reactive T cells, such as a 4-1BB agonist or a PD-1/PD-L1-blocking antibody, with another mAb that diversifies the pool of tumor-reactive T cells, such as a CTLA-4 blocking-antibody. This evidence concerns the gene CD274 and neoplasm.